Six pharmaceutical companies from around the world have signed on to be part of the $100 million Dementia Discovery Fund to help develop treatments than may slow or reverse dementia by 2025. Johnson & Johnson, Biogen, Lilly, GlaxoSmithKline, Takeda and Pfizer are the first drug companies to join the effort, but others will be invited in upcoming funding rounds. The fund is being managed by SV Life Sciences. The Telegraph (London) (tiered subscription model) (10/21)
Friday, October 23, 2015
6 major pharmaceutical companies join $100M Dementia Discovery Fund
If we had any leaders at all in stroke news like this would occur for stroke. But we have shit for leaders, not willing to try any BHAGs (Big Hairy Audacious Goals) at all. I blame the boards of directors for not setting goals like that for the presidents and choosing presidents who don't have an innovative thought in their brain.
Six pharmaceutical companies from around the world have signed on to be part of the $100 million Dementia Discovery Fund to help develop treatments than may slow or reverse dementia by 2025. Johnson & Johnson, Biogen, Lilly, GlaxoSmithKline, Takeda and Pfizer are the first drug companies to join the effort, but others will be invited in upcoming funding rounds. The fund is being managed by SV Life Sciences. The Telegraph (London) (tiered subscription model) (10/21)
Six pharmaceutical companies from around the world have signed on to be part of the $100 million Dementia Discovery Fund to help develop treatments than may slow or reverse dementia by 2025. Johnson & Johnson, Biogen, Lilly, GlaxoSmithKline, Takeda and Pfizer are the first drug companies to join the effort, but others will be invited in upcoming funding rounds. The fund is being managed by SV Life Sciences. The Telegraph (London) (tiered subscription model) (10/21)
There are over 9.9 million new cases of dementia each year worldwide,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment